EU Commission clears joint control of Immedica Pharma by Impilo and KKR
The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of Immedica Pharma by Impilo, both of Sweden, and by KKR of the US. The transaction relates primarily to the commercialization of medicines for rare diseases and specialty care products.